124 Plasma transforming growth factor β1 as a predictor of radiation pneumonitis

Autor: MS Anscher, FM Kong, K Andrews, R Clough, L Marks, G Bentel, RL Jirtle

Publikováno v: International Journal of Radiation Oncology*Biology*Physics. 39:197

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::851fe468bd3559c602aa06edafc3cf7e
https://doi.org/10.1016/s0360-3016(97)80682-7

Effect of 13-cis-retinoic acid and alpha-interferon on transforming growth factor beta1 in patients with rising prostate-specific antigen

Autor: Rs, Dipaola, Re, Weiss, Kb, Cummings, Fm, Kong, Rl, Jirtle, Mitchell Anscher, Gallo J, Goodin S, Thompson S, Rasheed Z, Aisner J, Mb, Todd

Publikováno v: Europe PubMed Central

The objective of this study was to test the hypothesis that 13-cis-retinoic acid (CRA) and alpha-interferon (IFN-alpha) have antitumor activity in patients with early recurrence of prostate cancer measured by rising prostate-specific antigen (PSA) af

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::610d8a7fd29082e31922fd1b66fb17ab
http://europepmc.org/abstract/med/9815590

Accelerated Hypofractionated Radiotherapy for Locally Advanced NSCLC: A Systematic Review From the International Association for the Study of Lung Cancer Advanced Radiation Technology Subcommittee.

Autor: Said BI; Division of Radiation Oncology, The University of Texas, M.D. Anderson Cancer Center, Houston, Texas; Department of Radiation Oncology, University of Toronto, Toronto, Ontario, Canada., Geng Y; Division of Radiation Oncology, The University of Texas, M.D. Anderson Cancer Center, Houston, Texas., Badiyan SN; Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, Texas., Bang A; BC Cancer Agency, Vancouver, British Columbia, Canada., Bezjak A; Department of Radiation Oncology, University of Toronto, Toronto, Ontario, Canada., Chua KLM; National Cancer Centre, Singapore, Singapore., Faivre-Finn C; The Christie NHS Foundation Trust, The University of Manchester, Manchester, United Kingdom., Kong FM; Department of Clinical Oncology, The University of Hong Kong, Hong Kong, People's Republic of China., Przybysz D; RadioSerra Radiation Therapy, Rio de Janeiro, Brazil., Putora PM; Department of Radiation Oncology, Kantonsspital St Gallen, St. Gallen, CH, Switzerland., Munoz-Schuffenegger P; Radiation Oncology Unit, Department of Hematology-Oncology, Pontificia Universidad de Chile, Santiago, Chile., Siva S; Department of Radiation Oncology, Peter MacCallum Cancer Centre and The University of Melbourne, Melbourne, Victoria, Australia., Xu-Welliver M; Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota., McDonald F; Department of Radiation Oncology, The Royal Marsden, London, United Kingdom., Louie A; Department of Radiation Oncology, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada., Chun SG; Division of Radiation Oncology, The University of Texas, M.D. Anderson Cancer Center, Houston, Texas. Electronic address: sgchun@mdanderson.org.

Publikováno v: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer [J Thorac Oncol] 2024 Sep 28. Date of Electronic Publication: 2024 Sep 28.

Comparing effectiveness of image perturbation and test retest imaging in improving radiomic model reliability.

Autor: Zhang J; Department of Health Technology and Informatics, The Hong Kong Polytechnic University, Y920, Lee Shau Kee Building, Hung Hom, Kowloon, Hong Kong, China., Teng X; Department of Health Technology and Informatics, The Hong Kong Polytechnic University, Y920, Lee Shau Kee Building, Hung Hom, Kowloon, Hong Kong, China., Zhang X; Department of Health Technology and Informatics, The Hong Kong Polytechnic University, Y920, Lee Shau Kee Building, Hung Hom, Kowloon, Hong Kong, China., Lam SK; Department of Biomedical Engineering, Faculty of Engineering, The Hong Kong Polytechnic University, Hong Kong, China.; Research Institute for Smart Ageing, The Hong Kong Polytechnic University, Hong Kong, China., Lin Z; Shenzhen Institute for Drug Control (Shenzhen Testing Center of Medical Devices), Shenzhen, China., Liang Y; Shenzhen Institute for Drug Control (Shenzhen Testing Center of Medical Devices), Shenzhen, China., Yu H; Institute of Biomedical and Health Engineering, Chinese Academy of Sciences Shenzhen Institutes of Advanced Technology, Shenzhen, China., Siu SWK; Department of Clinical Oncology, The University of Hong Kong, Hong Kong, China., Chang ATY; Department of Clinical Oncology, The University of Hong Kong, Hong Kong, China., Zhang H; Beijing Linking Medical Technology Co., Ltd., Beijing, China., Kong FM; Department of Clinical Oncology, The University of Hong Kong, Hong Kong, China.; Department of Clinical Oncology, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China., Yang R; Department of Radiation Oncology, Cancer Center, Peking University Third Hospital, Beijing, China., Cai J; Department of Health Technology and Informatics, The Hong Kong Polytechnic University, Y920, Lee Shau Kee Building, Hung Hom, Kowloon, Hong Kong, China. jing.cai@polyu.edu.hk.; Research Institute for Smart Ageing, The Hong Kong Polytechnic University, Hong Kong, China. jing.cai@polyu.edu.hk.; The Hong Kong Polytechnic University Shenzhen Research Institute, Shenzhen, China. jing.cai@polyu.edu.hk.

Publikováno v: Scientific reports [Sci Rep] 2023 Oct 25; Vol. 13 (1), pp. 18263. Date of Electronic Publication: 2023 Oct 25.

Regorafenib induces NOX5-mediated endoplasmic reticulum stress and potentiates the anti-tumor activity of cisplatin in non-small cell lung cancer cells.

Autor: Sui H; Cancer and Anticancer Drug Research Center, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang 325035, China; Wenzhou University-Wenzhou Medical University Collaborative Innovation Center of Biomedical, Wenzhou, 325035, China., Xiao S; Cancer and Anticancer Drug Research Center, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang 325035, China; Wenzhou University-Wenzhou Medical University Collaborative Innovation Center of Biomedical, Wenzhou, 325035, China; The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325000, China., Jiang S; Cancer and Anticancer Drug Research Center, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang 325035, China; Wenzhou University-Wenzhou Medical University Collaborative Innovation Center of Biomedical, Wenzhou, 325035, China., Wu S; Cancer and Anticancer Drug Research Center, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang 325035, China; Wenzhou University-Wenzhou Medical University Collaborative Innovation Center of Biomedical, Wenzhou, 325035, China., Lin H; Cancer and Anticancer Drug Research Center, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang 325035, China; The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325000, China., Cheng L; Cancer and Anticancer Drug Research Center, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang 325035, China; Wenzhou University-Wenzhou Medical University Collaborative Innovation Center of Biomedical, Wenzhou, 325035, China., Ye L; Cancer and Anticancer Drug Research Center, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang 325035, China; Wenzhou University-Wenzhou Medical University Collaborative Innovation Center of Biomedical, Wenzhou, 325035, China., Zhao Q; Cancer and Anticancer Drug Research Center, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang 325035, China; Wenzhou University-Wenzhou Medical University Collaborative Innovation Center of Biomedical, Wenzhou, 325035, China., Yu Y; Cancer and Anticancer Drug Research Center, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang 325035, China., Tao L; Cancer and Anticancer Drug Research Center, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang 325035, China., Kong FM; The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325000, China. Electronic address: Kong0001@hku.hk., Huang X; The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325000, China. Electronic address: zjwzhxy@126.com., Cui R; Cancer and Anticancer Drug Research Center, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang 325035, China; Wenzhou University-Wenzhou Medical University Collaborative Innovation Center of Biomedical, Wenzhou, 325035, China. Electronic address: wzmucuiri@163.com.

Publikováno v: Neoplasia (New York, N.Y.) [Neoplasia] 2023 May; Vol. 39, pp. 100897. Date of Electronic Publication: 2023 Mar 20.